The use of modified-release methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

Citation data:

Expert review of neurotherapeutics, ISSN: 1744-8360, Vol: 17, Issue: 2, Page: 113-121

Publication Year:
2017
Usage 12
Abstract Views 9
Link-outs 3
Captures 1
Readers 1
Citations 2
Citation Indexes 2
Repository URL:
https://touroscholar.touro.edu/tuncom_pubs/122, http://www.tandfonline.com/doi/abs/10.1080/14737175.2016.1271714?journalCode=iern20
PMID:
27936986
DOI:
10.1080/14737175.2016.1271714
Author(s):
Childress, Ann, Belchenko, Dmitry, Lempa, Brian
Publisher(s):
Informa UK Limited, Touro Scholar
Tags:
Neuroscience, Medicine, ADHD, Aptensio XR, attention-deficit/hyperactivity disorder, methylphenidate, methylphenidate extended-release, stimulants, Chemicals and Drugs, Medical Sciences
article description
Since Ritalin® (Methylphenidate-Immediate release or MPH-IR) was introduced for the treatment of attention-deficit/hyperactivity disorder, multiple formulations of MPH have been developed. The specific formulation determines the pharmacokinetic (PK) profile and the onset and duration of action for the compound. Areas covered: Aptensio XR® is a multilayer-release MPH (MPH-MLR) consisting of an MPH-IR layer (40%) and an extended-release (ER) portion of 60% of MPH. It has an initial maximum MPH concentration at about two hours (h) and a second concentration peak at approximately 8 h. This formulation allows for a rapid onset of effect by 1 h and a duration of action through 12 h after dosing. The chemistry, PK, efficacy and adverse event profile of MPH-MLR will be reviewed. Expert commentary: Although the PK profile may prove beneficial to patients in the late afternoon and early evening, it is not clear if this is a significant advantage compared with other MPH-ER formulations.

This article has 0 Wikipedia mention.